Clinical Trials

Several clinical trials are currently recruiting participants across diverse indications, including Alzheimer's disease, cognitive impairment, localized prostate carcinoma, traumatic rib fractures with acute or chronic pain, and postoperative pain tracking via smart device applications. Sponsored by academic and clinical entities such as C2N Diagnostics, IRCCS San Raffaele, Sunnybrook Health Sciences Centre, and Seoul National University Hospital, all studies report trial phases as unassigned or not applicable.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06025877 Recruiting
Alzheimer Disease|Mild Cognitive Impairment|Dementia|Cognitive Decline|Cognitive Impairment|Memory Impairment
C2N Diagnostics
2023-11-15 --
NCT05936736 Recruiting
Localized Prostate Carcinoma
IRCCS San Raffaele
2023-11-08 Not Applicable
NCT05865327 Recruiting
Rib Fractures|Rib Fracture Multiple|Rib; Fracture With Flail Chest|Pain|Pain Acute|Pain Chronic|Trauma|Trauma Injury
Sunnybrook Health Sciences Centre
2023-10-23 Not Applicable
NCT06014918 Recruiting
Mobile Applications|Pain Postoperative|Smartphone|Patient Satisfaction
Seoul National University Hospital
2023-08-28 Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Aluminum potassium sulfate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Aluminum potassium sulfate cross-links cell surface proteins and disrupts intracellular ion balance, triggering localized vascular thrombosis, tissue sclerosis, and disrupted neurotoxic signaling. This cellular protein precipitation and acute tissue response provide the biochemical basis for its sclerotherapeutic activity as well as its relevance to clinical conditions involving localized lesions, pain modulation, and cognitive impairment.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.